Study to Assess NBI-1065845 for Major Depressive Disorder (H-56829)

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)

If your current antidepressant medication(s) is/are not adequately improving symptoms of your MDD, you may be eligible for the AMPA Program.

Participation in one of the studies will last up to 14 weeks and includes eight study site visits. All participants will be able to remain on their current antidepressant medication(s) while taking part. Reimbursement may be available for applicable travel costs and inconveniences.

To participate in one of these studies, you must:

• Be at least 18 years old
• Have a primary diagnosis of MDD
• Be currently receiving at least 1 antidepressant medication
• Have had inadequate response to up to 5 oral antidepressant medications
• Not be pregnant, breastfeeding, or planning to become pregnant during the study

There are additional eligibility requirements, which the study team can explain to you.